SAGE Jan 2025 30.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
At close: 11:34AM EDT
Loading interactive chart...
- Zacks
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
- Simply Wall St.
Sage Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Sage Therapeutics ( NASDAQ:SAGE ) First Quarter 2024 Results Key Financial Results Revenue: US$7.90m (up 140% from 1Q...
- GuruFocus.com
Sage Therapeutics Inc (SAGE) Q1 2024 Earnings: Mixed Results Amidst Pipeline Progress
Revenue Beats Estimates, Losses Widen as Company Advances Brain Health Portfolio
© 2024 Yahoo. All rights reserved.